Empowering Cancer Drug Development
Overview
Oncova Biosciences is harnishing the breakhough powerful computational capacity of the Insilico Medicine (tm) digital drug development platform Chem42 (tm). This allows Oncova to target the Vital Oncogenes crucial to cancer development and progression.
Oncova Biosciences is an emerging, virtual Biotech cancer drug development company utilizing AI and in silico methodology to produce cancer drugs targeting novel previously resistant mutated genes that initiate and maintain cancer. Our relentless pursuit of innovation, coupled with a talented research team, drives us to the forefront of cancer drug development.
Our Mission
To transform oncology drug discovery through in silico technologies that accelerate and personalize the path to effective cancer therapeutics.
At Oncova Biosciences, our mission is to develop advanced biotechnological solutions to address critical medical challenges in cancer treatment and improve patient outcomes.
Meet Our Experts
The Minds Behind Oncova Biosciences
Rudolph Willis MD
President / CEO
Doctor Willis is the founder of Oncova Biosciences. He is a Theoretical Biologist with over 30 years' experience in all aspects of cancer therapy and research. He is the author of the foundational theoretical biology work and the designer of the Bioinformatic Database that serves as the basis for the development of a whole new class of targeted anti-cancer drugs.
​
Doctor Willis earned a combined biology and chemistry B.A. degree with honors at Northwestern University. He earned his M.D. degree at Washington University School of Medicine in St. Louis. He subsequently completed a fellowship at the National Cancer Institute at NIH, where he was a Research Associate in the Laboratory of Tumor Cell Biology.
​
He has participated in innumerable oncology clinical trials, and is the author of several scientific and clinical papers in oncology and molecular biology.
​
He is a member of the American Society of Clinical Oncology, American Society for Cell Biology, and a member of the NIH Alumni Association.
​
He is an adjunct Assistant Professor of Medicine at Drexel University College of Medicine in Philadelphia.
Scott Kahn PhD
Scientific Advisor
Doctor Kahn brings over 30 years of experience executing and directing top-level projects in academia and industry. Doctor Kahn combines a deep understanding of oncology, personalized medicine, translational research, biomarkers, and biomedical research with a high technical acumen and an acute mind for business development. He has directed projects alongside global thought leaders, worldwide industry and academic research groups, and cross-functional teams.
​
Doctor Kahn's many peer-reviewed research publications include seminal contributions to cancer biology and cancer theory. He has discovered oncogenes, functionally characterized signaling pathways, worked on associations between biomarkers and clinical therapy, and provided the first evidence leading to the theory of "Oncogene Addiction", a widely accepted theory for targeted drug therapy. Doctor Kahn has also conceived of, invented, and validated innovative, state of the art and cutting-edge biomarker platforms and functional assays.
​
Doctor Kahn has been a member of the Herbert Irving Comprehensive Cancer Center at Columbia University.
​
He completed his postdoctoral studies in the Herbert Irving Comprehensive Cancer Center at Columbia University, received his Ph.D. degree in Biochemistry and Molecular Biology from SUNY at Stoney Brook, and his B.A. degree with double majors in chemistry and biochemistry from Brandeis University.